Sentinel Node Biopsy for Thin Melanomas: Which Patient Should Be Considered?
Christopher A. Puleo, PA-C; Jane L. Messina, MD; Adam I. Riker, MD; L. Frank Glass, MD; Christopher Nelson, MD; C. Wayne Cruse, MD; Timothy M. Johnson, MD; Vernon K. Sondak, MD

Head and Neck Melanoma
Matthew A. Kienstra, MD; Tapan A. Padhya, MD

Choices in Adjuvant Therapy for Melanoma
David H. Lawson, MD

Cutaneous Melanoma: Prognostic Factors
Jade Homsi, MD, Mohammed Kashani-Sabet, MD, Jane L. Messina, MD, Adil Daud, MD

Chemoprevention of Melanoma: Theoretical and Practical Considerations
Marie-France Demierre, MD, FRCPC, Vernon K. Sondak, MD

Vaccines for Melanoma
C. Dean Buckner, MD

Radiofrequency Ablation Effective for Lung Tumors (7/22/2008)
Researchers involved in a multicenter international trial have reported that the use of radiofrequency ablation for the treatment of lung cancer or pulmonary metastases provides an effective and safe therapeutic option for selected patients. These results were recently published in the July 7, 2008 issue of Lancet Oncology.

Melanoma Rates Increasing in Young Women (7/15/2008)
Researchers from the National Cancer Institute have reported that rates of melanoma continue to increase among young women in the United States. These results appeared in an early online publication in the Journal of Investigative Dermatology on July 10, 2008.

Adjuvant Pegylated Interferon Improves Disease-free Survival in Patients with Stage III Melanoma (7/14/2008)
Researchers affiliated with the European Organization for Research and Treatment of Cancer (EORTC) have reported that adjuvant pegylated interferon alfa-2b increases recurrence-free survival in patients with Stage III melanoma. The details of this report appeared in the July 12, 2008 issue of The Lancet.

Primed Autologous CD4+ T Cells Produces Complete Remission in a Patient with Metastatic Melanoma (6/23/2008)
Researchers from the Fred Hutchinson Cancer Research Center have reported that a patient with metastatic melanoma responded completely to infusion of autologous CD4+ T cells with specificity for the melanoma-associated antigen NY-ESO-1. The details of this case report were published in the June 19, 2008 issue of the New England Journal of Medicine.

Nexavar® May Have Significant Activity in Advanced Melanoma (5/7/2008)
Researchers associated with a multicenter U.S. Phase II clinical trial have reported that the addition of Nexavar® (sorafenib) improves progression-free survival (PFS) in patients with advanced melanoma receiving dacarbazine. The details of this study appeared in the May 1, 2008 issue of the Journal of Clinical Oncology.